OrientSciences NewsPeptide and medical research from around the world, reported in English
5 min read
RegulationPeptide marketCompounding

HHS has cleared six peptides for compounding. What that changes for the peptide market, and what it does not

The US will not act against pharmacies compounding six peptides, on strict terms. What it means for supply, research-use-only sellers and the peptide market.

The headlines about the US decision on six peptides are now two weeks old, and the useful question has moved on from what happened to what changes. In late October the Department of Health and Human Services said it does not intend to take enforcement action against state licensed pharmacies, federal facilities and licensed physicians who compound BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500, provided they meet a list of conditions. It is an interim policy, issued while the FDA works through formal rulemaking on its list of bulk substances that pharmacies may use.

The short version is that access in the United States is likely to widen, but not in the form the grey market has supplied it. The detail sits in the conditions, and the conditions say a good deal about where the market is heading. This piece draws on law firm summaries of the notice, because the Federal Register text could not be opened for it.

What the policy actually allows

It is narrower than many headlines suggested. Each peptide is cleared only in specific forms and routes. BPC-157 acetate may be compounded for injection, oral or topical use. TB-500 and MOTS-c acetate are limited to injection, Epitalon acetate to injection in intermittent courses, KPV acetate to oral or topical use, and Semax free base to the nose.

Each product may contain a single active ingredient, which rules out the blends that have become popular. It still needs an individual prescription and a label stating that it is compounded and not for resale, and the only device that may be packed with it is an FDA cleared syringe. Compounders must also report serious adverse events and quality problems to the FDA and to the states.

The certificate is the real gate

The condition most likely to shape the market is about supply. The bulk peptide must come from a facility registered with the FDA, and the original manufacturer must follow current good manufacturing practice. It must arrive with a certificate of analysis that names the manufacturing facility, states that the material is intended for human drug compounding and carries the quality unit's signature. A basic research grade certificate does not qualify. Identity has to be confirmed by at least two orthogonal methods, with testing for residual trifluoroacetic acid, solvents and elemental impurities, and for injectables endotoxin and bioburden as well.

Permission to compound has, in effect, been tied to a documentation standard that most research-use-only material does not meet. If a reseller sits in the chain, the pharmacy must document that it has validated the original manufacturer. One law firm's analysis makes the point neatly: a certificate is only as reliable as the factory behind it.

Who is left outside

HHS was open about the purpose. Its notice says it aims to discourage widespread use of research-use-only peptides from foreign manufacturers by offering patients "a more controlled alternative." Law firm analyses agree that the policy gives research-use-only sellers no protection and does not change the legal status of research-use-only peptides. It does not cover 503B outsourcing facilities either, the larger operations that make products in bulk.

For researchers the useful effect is a sharper line. Laboratory material stays laboratory material, bought for analysis. The question of use in people moves into a regulated pharmacy channel with its own standards, and the market will increasingly organise itself around that line.

Why HHS moved

Demand is the reason. In a preprint analysis of clinical notes from one database, newly confirmed BPC-157 users rose from 4 in early 2020 to 134 in early 2026. Of 205 users who recorded a source, 36 percent had obtained it through a compounding pharmacy and 35 percent from a gray-market vendor. It is one database and a preprint, so it shows direction, not the size of the market. HHS itself says it believes there is significant interest in compounding these peptides given the lack of approved products.

How long it lasts

Nothing here is settled. The policy is a draft that creates no legal rights, and HHS can narrow or withdraw it. It runs until the FDA finalises a bulks list rule, and the comment period closed on 13 November. The FDA's advisory committee narrowly voted in July to recommend the six, in each case against the advice of the agency's own drug centre, and a second meeting on five more peptides is not expected until early 2027. Emideltide, the seventh peptide reviewed, was left out. State pharmacy boards can be stricter than the federal policy.

The evidence gap has not closed either. A pharmacist's analysis notes that moving a peptide into compounding decides whether a pharmacy may prepare it, not whether it works: it confers no approval, no validated indication and no standard dose.

Supply, and the view from Europe

The supply chain is where the documentation standard will bite. The same law firm analysis lists FDA warning letters this year to Chinese manufacturers, two of which were placed on an import alert in October, and reports that unannounced FDA inspections in China rose from 19 percent of the total in fiscal 2025 to 61 percent in fiscal 2026. A consultancy that works with outsourcing facilities forecast in March that demand would return to regulated manufacturing on compressed timelines, with tighter bulk supply and more volatile pricing at first. For any supplier, documentation traceable to a named, inspected facility is becoming the price of entry.

None of this changes European or British law. In the EU the EMA authorises medicines while member states enforce their own pharmacy and prescription rules, and in the UK the MHRA decides case by case whether a product is a medicine. An enforcement policy in Washington is not an approval, and it carries no weight in Brussels or London. What may travel is the standard: buyers elsewhere can be expected to ask for the same facility-level paperwork.

What is still unknown

Three things will decide how durable this is: the FDA's proposed bulks list rule, the second advisory committee meeting in early 2027, and whether Congress writes peptide provisions into the FDA funding bills or the compounding legislation now being discussed.

SOURCES AND FURTHER READING

Share this update

Share this update: https://orientsciences.com/news/hhs-six-peptides-compounding-what-it-means-for-the-peptide-market

View all weekly news